Our in vitro experiments confirmed the role of inflammation and oxidative stress as the main instigators of impaired immunity in diabetes as combined pharmacological intervention with a PKC inhibitor and an antioxidant targeting the ROS generator, NADPH oxidase, but not either agent alone, reversed the molecular dysregulation initiated by common molecular assaults of diabetes and restored a prompt immune response of renal epithelial cells. Here, FMO5 is linked to diabetes mellitus.